China’s CAR-T Therapy Race – Pharmaceutical Executive (press release) (blog)
Pharmaceutical Executive |
China's CAR–T Therapy Race
Pharmaceutical Executive (press release) (blog) On March 12, 2018 the Chinese FDA (CFDA) approved the clinical trial application of LCAR-B38M CAR–T cell self-reinfusion preparation from Nanjing Legend Biotech, marking the first cellular therapy to officially enter the clinical trial stage in China … Dendritic Cell and CAR–T Therapies Market Trends and Segments 2017 – 2025 |
